Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Endocarditis II: Clinical Features of Infective Endocarditis01:25

Endocarditis II: Clinical Features of Infective Endocarditis

919
Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...
919
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

1.1K
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
1.1K
Overview of Systemic Arteries01:11

Overview of Systemic Arteries

2.6K
The human body is a complex, well-organized machine, and at the heart of its operations lies the circulatory system. This network of blood vessels, which includes systemic arteries, plays a vital role in maintaining life by transporting nutrients, oxygen, and waste products to and from cells throughout the body.
Systemic circulation is the part of the cardiovascular system that carries oxygenated blood away from the heart to the body's tissues and returns deoxygenated blood back to the...
2.6K
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

1.3K
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
1.3K
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

1.0K
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
1.0K
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

407
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
407

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Joint hypermobility syndrome].

Acta ortopedica mexicana·2021
Same author

Development and initial validation of a damage index (DIAPS) in patients with thrombotic antiphospholipid syndrome (APS).

Lupus·2015
Same author

Multibacillary leprosy mimicking systemic lupus erythematosus: case report and literature review.

Lupus·2015
Same author

Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study.

Annals of the rheumatic diseases·2014
Same author

Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus.

Annals of the rheumatic diseases·2005
Same author

Subcutaneous administration of collagen-polyvinylpyrrolidone down regulates IL-1beta, TNF-alpha, TGF-beta1, ELAM-1 and VCAM-1 expression in scleroderma skin lesions.

Clinical and experimental dermatology·2005

Related Experiment Video

Updated: Apr 27, 2026

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

2.6K

Vasculitis in systemic lupus erythematosus.

L Barile-Fabris1, M F Hernández-Cabrera, J A Barragan-Garfias

  • 1Rheumatology Department, Hospital de Especialidades. Centro Médico Nacional Siglo XXI "Bernardo Sepúlveda", Instituto Mexicano del Seguro Social, Avda. San Bernabé, 712 Bis, casa 3. San Jerónimo Lídice. C.P. 10,200, Mexico, Mexico, barilita@yahoo.com.

Current Rheumatology Reports
|July 16, 2014
PubMed
Summary

Systemic lupus erythematosus (SLE) vasculitis affects various organs and vessel sizes, presenting diverse clinical forms. Early recognition and novel treatments like biologics are crucial for managing this complex autoimmune condition.

More Related Videos

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

17.7K
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

22.1K

Related Experiment Videos

Last Updated: Apr 27, 2026

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

2.6K
The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

17.7K
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

22.1K

Area of Science:

  • Rheumatology
  • Immunology
  • Internal Medicine

Background:

  • Systemic lupus erythematosus (SLE) is a complex autoimmune disease with diverse clinical and serological manifestations.
  • Vasculitis affects 11-36% of SLE patients, involving vessels of all sizes and leading to varied clinical presentations.
  • While cutaneous lesions (small vessel vasculitis) are common, medium and large vessel vasculitis can cause severe, life-threatening visceral complications.

Purpose of the Study:

  • To highlight the diverse clinical spectrum of vasculitis in SLE.
  • To emphasize the importance of early recognition and appropriate treatment for SLE-related vasculitis.
  • To discuss recent advancements in understanding and treating SLE vasculitis, including emerging biologic therapies.

Main Methods:

  • Review of recent literature on SLE-associated vasculitis.
  • Analysis of clinical presentations based on organ involvement and vessel size.
  • Examination of current and emerging therapeutic strategies.

Main Results:

  • SLE vasculitis presents a broad clinical spectrum, from cutaneous lesions to severe visceral disease (e.g., mesenteric vasculitis, pulmonary hemorrhage).
  • Vasculitis episodes in SLE are not always associated with high systemic disease activity.
  • Recent research focuses on novel treatments, including biologics like Rituximab and Belimumab, for vascular manifestations.

Conclusions:

  • Understanding the varied clinical forms of SLE vasculitis is essential for timely diagnosis and management.
  • Effective treatment strategies, including biologics, are evolving for SLE-associated vasculitis.
  • Prompt intervention is critical to mitigate the detrimental consequences of SLE vasculitis.